CBD for Epilepsy: What the Evidence Establishes and What It Does Not

Medical cannabis collection · Sources reviewed 11 October 2026

Epilepsy provides one of the clearest examples of a cannabinoid becoming a medicine through controlled research. The important words are the name of the preparation, the epilepsy syndrome and the outcome measured. The evidence is considerably more specific than the claim that cannabis treats seizures.

Which epilepsies and which medicine?

Epidyolex is a standardised oral cannabidiol medicine. In the UK product information it is indicated, with clobazam, as additional treatment for seizures associated with Dravet syndrome or Lennox–Gastaut syndrome from age two. It is also indicated as additional treatment for tuberous sclerosis complex-associated seizures from age two. These boundaries matter: evidence for these syndromes does not establish benefit for every epilepsy or for an unidentified retail oil. UK product information.

US and European labels are not identical. An age threshold copied from an American page should not silently replace the instructions for a UK medicine. A neurologist also needs to consider which seizure types are being counted and how the diagnosis was established.

What the Dravet trial actually found

In the 2017 randomised trial, 120 children and young adults continued their usual antiseizure treatment and received CBD or placebo. Median monthly convulsive seizures fell from 12.4 to 5.9 in the CBD group, compared with 14.9 to 14.1 in the placebo group over the treatment period. Adverse events and withdrawals were more frequent with CBD. Devinsky and colleagues, 2017.

The result supports a specific benefit, while leaving seizures present for many participants. It should not be rewritten as a cure. Nor should a relative reduction in one seizure category be described as an equivalent improvement in learning, development or every aspect of family life. Those are important outcomes that need their own measurement.

Why the other medicines matter

CBD can alter exposure to other medicines. The product information describes an interaction with clobazam’s active metabolite and an increased concern about liver-enzyme elevations with valproate. This is one reason a change can affect both seizure control and alertness. Blood-test monitoring and a review of the complete treatment regimen help the clinical team interpret the result.

Families should also have clear instructions about administration, food and missed or vomited doses. Changes in a child’s feeding routine can be clinically relevant. The answer is coordinated advice from the epilepsy team, rather than improvising a conversion between a prescription solution and another CBD product.

A useful seizure record

Counting alone can miss an important change. A reduction in one seizure type with worse sedation is a mixed outcome; fewer emergency interventions may be valuable even if seizures continue. Caregiver observations should be discussed alongside clinical assessments and laboratory results.

Why retail CBD is not a substitute

A product’s stated CBD content does not establish that it matches the formulation, quality controls or evidence of a licensed medicine. The EMA assessment concerns the particular product and its benefits and risks. It does not certify all oils carrying the same ingredient name. European Medicines Agency assessment.

Do not stop or replace antiseizure treatment because a new product is described as natural. The useful lesson from prescription CBD is that cannabinoid treatment can have a defined medical role when the diagnosis, preparation, monitoring and outcomes are made explicit.

Educational information, not an individual prescribing plan. Decisions about medicines belong with the treating clinician. External reference links open in a new tab.